LAVA Therapeutics Gamma-Delta T Cell Cancer 2024

LAVA Therapeutics presents its proprietary Gammabody® platform for gamma-delta T cell engagers targeting multiple cancer types including mCRPC, AML, and NSCLC. The company's lead program LAVA-1207 is enrolling in Phase 1/2a trials with strategic partnerships from Pfizer and Johnson & Johnson, backed by $95 million in cash with runway into 2026.